PURE Bioscience (PURE.OB) Reports Year End Results
PURE Bioscience (PURE.OB), creators of patented silver dihydrogen citrate (SDC), the active ingredient in disinfectants that kill Staph/MRSA as well as other human pathogens, reported financial results for the year ended July 31, 2007. Revenues for PURE totaled $336,400, an increased of 68% when compared to revenues of $200,432 in the prior year. The Company also reported a loss from operations before taxes of $(4,840,800), or $(0.19) per share, compared with a loss of $(3,712,600), or $(0.19) per share, in the prior year. Michael L. Krall, President and CEO of PURE Bioscience, stated "In fiscal 2007 we continued to lay…